Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
Phase 3 clean clinical trial is exceeding 50 % entry with new study site activities, which is expected to be ...
Read more
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
Lyell Immunopharma, Inc Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR ...
Read more
